About this trial
Amyloid deposition in the heart is called cardiac amyloidosis (CA); 95% is immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). Hereditary (ATTRm) or wild-type (ATTRwt) depends on whether the ATTRm gene is mutated or not. The most common mutation in Taiwan is A97S, 80% have left ventricular hypertrophy. The good prognosis depends on early diagnosis and correct treatment strategy.
Bone-avid tracers such as 99mTc-PYP/DPD/HMDP could detect CA. The mechanism is not clear yet, which may be related to the microcalcification. AL amyloidosis is mostly between visual score grade 0-2, and ATTR-CM is usually grade≥2 on PYP scan, or heart to contralateral (H/CL) ratio, and it might replace invasive myocardial biopsy. However, there are no large-scale clinical studies, lack of standardization data, and limited information in comparison between clinical and imaging parameters.
The project will enroll patients with suspected or diagnosed with CA according to CA diagnostic algorithm. Clinical data and image parameters are collected and compared. The project aims to set up prediction models based on the multi-parameters of PYP scan using artificial intelligence technology, including imaging registration and alignment technology, and standardization. The investigators further use the key cardiovascular data elements and imaging-derived database using model training network to extract image features to develop the diagnostic and prognostic prediction models, which are expected to validate the clinical significance and improve patient-centric performance and efficient clinical decision making.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
≥ 20 years of age
Documented diagnosis or r/o of ATTR amyloidosis
Disqualifiers
Pregnant or nursing (lactating) women.
Important systemic diseases (except heart disease or neurological diseases) such as liver cirrhosis, active malignant tumors, etc., with a life expectancy of less than 6 months.
Patient who refused clinical follow up.
Trial population
Patients screened for ATTR-CM
Trial design
Case-only
Other
Treatments tested in this trial
Tc-99m PYP Cardiac scan
Diagnostic testTc-99m PYP Cardiac scan
Treatment groups
Trial outcomes
Primary outcomes
Death
Death
Secondary outcomes
CV death
CV death
Hospitalization for heart failure
Hospitalization for heart failure
Sponsors and contacts
Click on the lead sponsor to view all of their trials.